» Articles » PMID: 17956988

Unraveling the Hidden Catalytic Activity of Vertebrate Class IIa Histone Deacetylases

Overview
Specialty Science
Date 2007 Oct 25
PMID 17956988
Citations 273
Authors
Affiliations
Soon will be listed here.
Abstract

Previous findings have suggested that class IIa histone deacetylases (HDACs) (HDAC4, -5, -7, and -9) are inactive on acetylated substrates, thus differing from class I and IIb enzymes. Here, we present evidence supporting this view and demonstrate that class IIa HDACs are very inefficient enzymes on standard substrates. We identified HDAC inhibitors unable to bind recombinant human HDAC4 while showing inhibition in a typical HDAC4 enzymatic assay, suggesting that the observed activity rather reflects the involvement of endogenous copurified class I HDACs. Moreover, an HDAC4 catalytic domain purified from bacteria was 1,000-fold less active than class I HDACs on standard substrates. A catalytic Tyr is conserved in all HDACs except for vertebrate class IIa enzymes where it is replaced by His. Given the high structural conservation of HDAC active sites, we predicted the class IIa His-Nepsilon2 to be too far away to functionally substitute the class I Tyr-OH in catalysis. Consistently, a Tyr-to-His mutation in class I HDACs severely reduced their activity. More importantly, a His-976-Tyr mutation in HDAC4 produced an enzyme with a catalytic efficiency 1,000-fold higher than WT, and this "gain of function phenotype" could be extended to HDAC5 and -7. We also identified trifluoroacetyl-lysine as a class IIa-specific substrate in vitro. Hence, vertebrate class IIa HDACs may have evolved to maintain low basal activities on acetyl-lysines and to efficiently process restricted sets of specific, still undiscovered natural substrates.

Citing Articles

Enzyme-independent functions of HDAC3 in the adult heart.

Qian S, Zhang C, Li W, Song S, Lin G, Cheng Z bioRxiv. 2025; .

PMID: 39803453 PMC: 11722435. DOI: 10.1101/2024.12.29.630635.


HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.

Minisini M, Mascaro M, Brancolini C Cancer Drug Resist. 2024; 7:46.

PMID: 39624079 PMC: 11609180. DOI: 10.20517/cdr.2024.103.


Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?.

Raouf Y, Moreno-Yruela C JACS Au. 2024; 4(11):4148-4161.

PMID: 39610753 PMC: 11600154. DOI: 10.1021/jacsau.4c00828.


Distribution and diversity of classical deacylases in bacteria.

Graf L, Moreno-Yruela C, Qin C, Schulze S, Palm G, Schmoker O Nat Commun. 2024; 15(1):9496.

PMID: 39489725 PMC: 11532494. DOI: 10.1038/s41467-024-53903-0.


Histone deacetylase 7 activates 6-phosphogluconate dehydrogenase via an enzyme-independent mechanism that involves the N-terminal protein-protein interaction domain.

Wang Y, Curson J, Ramnath D, Das Gupta K, Reid R, Karunakaran D Biochem J. 2024; 481(21):1569-1584.

PMID: 39373581 PMC: 11555707. DOI: 10.1042/BCJ20240380.


References
1.
Jin Y, Jeon E, Li Q, Lee Y, Choi J, Kim W . Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem. 2004; 279(28):29409-17. DOI: 10.1074/jbc.M313120200. View

2.
Inoue A, Fujimoto D . Histone deacetylase from calf thymus. Biochim Biophys Acta. 1970; 220(2):307-16. DOI: 10.1016/0005-2744(70)90015-x. View

3.
Chang S, McKinsey T, Zhang C, Richardson J, Hill J, Olson E . Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004; 24(19):8467-76. PMC: 516756. DOI: 10.1128/MCB.24.19.8467-8476.2004. View

4.
Vega R, Matsuda K, Oh J, Barbosa A, Yang X, Meadows E . Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell. 2004; 119(4):555-66. DOI: 10.1016/j.cell.2004.10.024. View

5.
Gregoretti I, Lee Y, Goodson H . Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004; 338(1):17-31. DOI: 10.1016/j.jmb.2004.02.006. View